Adherex Technologies (FENC) Competitors $8.47 -0.33 (-3.75%) As of 07/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FENC vs. MLYS, PHVS, NRIX, ORIC, MDXG, PRAX, LENZ, CRMD, OCS, and RCUSShould you be buying Adherex Technologies stock or one of its competitors? The main competitors of Adherex Technologies include Mineralys Therapeutics (MLYS), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Oric Pharmaceuticals (ORIC), MiMedx Group (MDXG), Praxis Precision Medicines (PRAX), LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), and Arcus Biosciences (RCUS). These companies are all part of the "med - biomed/gene" industry. Adherex Technologies vs. Its Competitors Mineralys Therapeutics Pharvaris Nurix Therapeutics Oric Pharmaceuticals MiMedx Group Praxis Precision Medicines LENZ Therapeutics CorMedix Oculis Arcus Biosciences Adherex Technologies (NASDAQ:FENC) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Is FENC or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -45.52%. Adherex Technologies' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adherex Technologies-45.52% N/A -26.37% Mineralys Therapeutics N/A -71.15%-65.71% Do analysts recommend FENC or MLYS? Adherex Technologies presently has a consensus price target of $13.00, indicating a potential upside of 53.48%. Mineralys Therapeutics has a consensus price target of $32.25, indicating a potential upside of 138.36%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has preferable valuation & earnings, FENC or MLYS? Adherex Technologies has higher revenue and earnings than Mineralys Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdherex Technologies$47.54M4.92-$440K-$0.51-16.61Mineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.63 Does the media prefer FENC or MLYS? In the previous week, Adherex Technologies had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 4 mentions for Adherex Technologies and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.53 beat Adherex Technologies' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in FENC or MLYS? 55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 11.0% of Adherex Technologies shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, FENC or MLYS? Adherex Technologies has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. SummaryAdherex Technologies beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get Adherex Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.88M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-16.6120.4427.2220.08Price / Sales4.92190.25381.5993.26Price / Cash272.4841.7026.2128.59Price / Book-40.337.397.945.55Net Income-$440K-$55.04M$3.17B$248.49M7 Day Performance2.05%2.51%1.79%4.87%1 Month Performance0.47%-0.21%1.27%6.63%1 Year Performance45.78%3.41%33.57%20.38% Adherex Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCAdherex Technologies1.7075 of 5 stars$8.47-3.8%$13.00+53.5%+45.8%$242.88M$47.54M-16.6110News CoverageMLYSMineralys Therapeutics2.1338 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A-3.6328PHVSPharvaris1.7441 of 5 stars$17.60+3.5%$36.20+105.7%+8.1%$888.93MN/A-5.8530Positive NewsGap UpNRIXNurix Therapeutics1.6053 of 5 stars$11.39-2.1%$30.18+164.9%-36.5%$887.38M$54.55M-4.07300Upcoming EarningsORICOric Pharmaceuticals4.2207 of 5 stars$10.15-1.6%$19.17+88.8%+38.5%$878.66MN/A-5.4380MDXGMiMedx Group3.4131 of 5 stars$6.11+2.9%$12.50+104.6%-4.6%$877.35M$348.88M22.63870PRAXPraxis Precision Medicines2.9381 of 5 stars$42.05-2.2%$109.90+161.4%+15.8%$875.87M$8.55M-3.92110LENZLENZ Therapeutics1.3238 of 5 stars$29.31-2.9%$46.60+59.0%+74.4%$849.45MN/A-16.56110CRMDCorMedix2.7477 of 5 stars$12.32-1.4%$17.14+39.1%+177.2%$847.81M$43.47M56.0030High Trading VolumeOCSOculis1.7349 of 5 stars$19.41+0.3%$35.33+82.0%+60.7%$844.87M$780K-7.352RCUSArcus Biosciences2.7732 of 5 stars$8.17+2.8%$21.29+160.5%-41.7%$841.79M$258M-1.95500 Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Oric Pharmaceuticals Alternatives MiMedx Group Alternatives Praxis Precision Medicines Alternatives LENZ Therapeutics Alternatives CorMedix Alternatives Oculis Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FENC Stock Alerts